OncoMatch/Clinical Trials/NCT06166576
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis
Is NCT06166576 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
The RESOLVE trial, an open-label, single-arm, multi-center study, aims to assess the efficacy and safety of ablative radioembolization using TheraSphere Yttrium-90 microspheres. This trial specifically targets patients diagnosed with hepatocellular carcinoma accompanied by localized portal vein tumor thrombosis (Vp1-Vp3) and who maintain good liver function.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Leukocytes ≥ 2,500/µL and ≤ 12,000/µL; Absolute neutrophil count ≥ 1,500/mm^3; Hemoglobin ≥ 8.0 g/dL (transfusions allowed); Platelets ≥ 50,000/µL; For patients not on anticoagulants, INR ≤ 2.0
Kidney function
Creatinine ≤ 2.0 mg/dL
Liver function
Total bilirubin ≤ 3.0 mg/dL; AST ≤ 200 IU/L (≤ 5X ULN); ALT ≤ 200 IU/L (≤ 5X ULN); ALP ≤ 575 IU/L (≤ 5X ULN); Child-Pugh class A
Patients without serious dysfunction of major organs, as indicated by blood tests conducted within one month of study enrollment 1. Leukocytes ≥ 2,500/µL and ≤ 12,000/µL 2. Absolute neutrophil count ≥ 1,500/mm^3 3. Hemoglobin ≥ 8.0 g/dL (transfusions allowed to meet this criterion) 4. Total bilirubin ≤ 3.0 mg/dL 5. Platelets ≥ 50,000/µL 6. For patients not on anticoagulants, INR ≤ 2.0 7. AST ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) 8. ALT ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) 9. ALP ≤ 575 IU/L (i.e., ≤ 5X upper normal limit) 10. Creatinine ≤ 2.0 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06166576 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages